STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Paris:TNG) (Euronext; TNG) today announced its upcoming events calendar for the fourth quarter of 2014.
Jefferies Global Healthcare Conference: Transgene will give a corporate presentation on November 19. The conference will be held in London, UK.
Portzamparc Biotech Seminar: Transgene will meet with investors at this event, which is being held on November 25 in Paris, France.
German Equity Forum: Transgene will give a corporate presentation on November 25 at 4 PM CET. The conference will be held in Frankfurt, Germany.
The Company also announced that data from the Phase 2b part of the Phase 2b/3 TIME trial will be presented at two upcoming medical meetings in the US:
ASCO Chicago Multidisciplinary Symposium in Thoracic Oncology: Data will be presented in a poster entitled: TIME, a phase 2b/3 study evaluating TG4010 in combination with first line therapy in advanced non small cell lung cancer (NSCLC), Phase 2b results (Poster board #172). The symposium is being held October 30-November 1 in Chicago, Illinois.
Society for Immunotherapy of Cancer (SITC)'s 29th Annual Meeting: An oral presentation, TG4010 immunotherapy combined with first-line therapy in advanced non-small cell lung cancer (NSCLC): Phase 2b results of the TIME study, will be given by John Nemunaitis, MD, Executive Medical Director of Mary Crowley Cancer Research Centers on November 7. The meeting is being held in National Harbor, Maryland.
About Transgene
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a publicly traded French biopharmaceutical company focused on discovering, developing and manufacturing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize well-tolerated viruses with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
Société anonyme au capital de 87.954.029,39 € – R.C. Strasbourg B 317
540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation -
CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33
(0)3 88 27 91 00 - Fax : + 33 (0)3 88 27 91 11
